Blog
Clinical evidence insights, methodology deep-dives, and the latest in clinical decision support from the Ailva team.
KDIGO 2026 CKD Guidelines: Key Updates for Nephrology Practice
The 2026 KDIGO guidelines introduce significant changes to CKD staging, SGLT2 inhibitor recommendations, and GLP-1 agonist integration. Here is what changed and what it means for your patients.
SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points
DAPA-HF and EMPEROR-Reduced established SGLT2 inhibitors as foundational HFrEF therapy. DELIVER and EMPEROR-Preserved extended the benefit to HFpEF. Here is the trial-by-trial evidence and practical prescribing guidance for your heart failure patients.
Type 2 Diabetes Management 2026: ADA Standards of Care Updates
The 2026 ADA Standards of Care introduce updated guidance on GLP-1 agonist and GLP-1/GIP dual agonist positioning, cardiovascular risk reduction, and technology-assisted management. Key changes for primary care and endocrinology practice.
Alzheimer's Disease Treatment 2026: Anti-Amyloid Antibodies and Beyond
Lecanemab and donanemab demonstrated meaningful clinical benefit in amyloid-positive early Alzheimer's disease. This review covers the evidence, ARIA monitoring, patient selection criteria, and the emerging treatment landscape for neurologists and primary care physicians.
Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond
EAST-AFNET 4 shifted the paradigm toward early rhythm control in AF, demonstrating a 21% reduction in cardiovascular outcomes. This review examines the evolving evidence for rhythm control strategies, DOAC selection, and catheter ablation outcomes in the context of current guidelines.
Psoriasis Biologics: IL-17 vs IL-23 Inhibitors in Head-to-Head Trials
Biologic therapy for moderate-to-severe psoriasis now includes multiple IL-17 and IL-23 inhibitors with PASI 90 and PASI 100 rates exceeding 60-80%. This review summarizes head-to-head trial data comparing these mechanisms and guides clinical selection based on efficacy, durability, and safety.
HIV PrEP and Treatment: Long-Acting Injectable Cabotegravir and Lenacapavir
Long-acting injectable HIV prevention and treatment have transformed adherence paradigms. This review covers cabotegravir for PrEP, lenacapavir as a twice-yearly option, and injectable cabotegravir/rilpivirine for treatment, with efficacy data and practical implementation considerations.
Acute Kidney Injury: KDIGO Staging, Prevention Strategies, and Recovery Prediction
AKI affects 10-15% of hospitalized patients and up to 50% of ICU patients, with significant implications for long-term CKD progression and mortality. This review covers KDIGO staging, nephrotoxin stewardship, hemodynamic optimization, and emerging biomarkers for early detection and recovery prediction.
Stroke Prevention: Carotid Stenosis Management and Dual Antiplatelet Therapy Evidence
Management of carotid stenosis and post-stroke antiplatelet strategy have evolved with the CREST-2 and POINT/CHANCE trial data. This review covers the indications for carotid endarterectomy versus stenting, the time-limited dual antiplatelet approach, and the role of intensive medical management.
Clostridioides difficile Infection: Fidaxomicin vs Vancomycin and FMT Evidence
Recurrent C. difficile infection affects 25-35% of patients after initial treatment. This review compares fidaxomicin and vancomycin head-to-head trial data, evaluates tapered-pulsed regimens, and summarizes the pivotal fecal microbiota transplantation evidence including FDA-approved live biotherapeutics.
Hypertension Management: 2026 ACC/AHA Blood Pressure Targets and Treatment Updates
The 2026 ACC/AHA hypertension guidelines refine blood pressure targets and first-line therapy recommendations based on SPRINT, STEP, and ESPRIT trial data. This review provides a practical algorithm for initial drug selection, combination therapy, and resistant hypertension management.
Opioid Use Disorder: Buprenorphine Induction and Maintenance Evidence
Buprenorphine-based medication for opioid use disorder reduces mortality by 50% and is now accessible without the X-waiver in the United States. This review covers induction protocols including low-dose strategies, maintenance dosing, and the evidence for extended-release injectable formulations.
Atopic Dermatitis: Dupilumab, JAK Inhibitors, and Emerging Therapies
The treatment landscape for moderate-to-severe atopic dermatitis has expanded dramatically with multiple targeted therapies. This review compares dupilumab, tralokinumab, and JAK inhibitors using pivotal trial data and provides a practical positioning algorithm for dermatologists.
Sleep Apnea and Cardiovascular Risk: CPAP Evidence and Alternatives
Obstructive sleep apnea affects an estimated 1 billion adults globally and is independently associated with hypertension, atrial fibrillation, and heart failure. This review examines the SAVE trial findings on CPAP and cardiovascular outcomes, mandibular advancement devices, and hypoglossal nerve stimulation evidence.
Heart Valve Disease: TAVR Expansion to Lower-Risk and Younger Patients
Transcatheter aortic valve replacement has expanded from prohibitive-risk to low-risk patients within a decade. This review covers the PARTNER 3 and Evolut Low Risk trial data, durability concerns, lifetime management considerations for younger patients, and evolving indications for transcatheter mitral and tricuspid interventions.
Aortic Stenosis Severity Assessment: Echo Parameters and Decision Timing
Echocardiographic grading of aortic stenosis relies on aortic valve area, mean gradient, and peak velocity, but discordant findings occur in up to 30% of cases. This review covers current severity classification, low-flow low-gradient subtypes, and optimal timing for surgical or transcatheter intervention.
Melanoma Staging and Treatment: Immunotherapy and Targeted Therapy
The 5-year survival rate for metastatic melanoma has improved from 5% to over 50% with immunotherapy and targeted therapy. Current treatment selection depends on BRAF mutation status, disease stage, and patient performance status, with adjuvant and neoadjuvant approaches expanding rapidly.
Chronic Hepatitis B: Tenofovir, Entecavir, and Functional Cure Strategies
Approximately 296 million people worldwide have chronic hepatitis B infection. First-line nucleos(t)ide analog therapy with tenofovir or entecavir achieves viral suppression in over 95% of patients, while functional cure strategies targeting HBsAg loss represent the next therapeutic frontier.
Pediatric Obesity: GLP-1 Agonist Approval and Multidisciplinary Management
Pediatric obesity now affects 19.7% of US children and adolescents. FDA approval of semaglutide and liraglutide for adolescents has expanded pharmacotherapy options, but optimal outcomes require integration with intensive behavioral and dietary interventions.
Cervical Cancer Screening: HPV Primary Testing and Updated Intervals
Cervical cancer screening guidelines now endorse HPV primary testing as a preferred strategy for women aged 25-65. Extended screening intervals of 5 years with HPV testing alone or co-testing improve detection of high-grade lesions while reducing unnecessary colposcopy.
Obesity Pharmacotherapy: Semaglutide, Tirzepatide, and Combination Approaches
The obesity pharmacotherapy landscape has been transformed by GLP-1 and dual GLP-1/GIP receptor agonists achieving 15-25% total body weight loss. This review compares approved agents, emerging combination therapies, and evidence-based patient selection criteria.
Myasthenia Gravis: FcRn Inhibitors and Complement-Directed Therapies
The myasthenia gravis treatment landscape has been revolutionized by targeted therapies, with FcRn inhibitors and complement inhibitors achieving rapid, clinically meaningful improvement in generalized disease. These agents offer new options for refractory patients and may reshape the treatment paradigm.
GLP-1 Receptor Agonists Beyond Diabetes: Cardiovascular and Renal Evidence
SELECT proved semaglutide cuts MACE in patients without diabetes. FLOW stopped early because semaglutide slowed CKD progression that dramatically. Here is what the trials actually show, and what they mean for the patient in your office tomorrow.
Why Clinical AI Tools Hallucinate Citations — And How to Verify Them
A colleague asked me to check a citation from an AI clinical summary. The paper it referenced — a 2023 Lancet meta-analysis — did not exist. The authors were real. The journal was real. The study was fabricated. Studies show this happens up to 47% of the time.
Clinical Citation Verification: A Comprehensive Guide for Healthcare Professionals
Why clinical citations hallucinate, the types of hallucinations that matter most, and how verification systems work. A comprehensive guide for any healthcare professional relying on evidence-based tools.
Drug-Nutrient Interactions Physicians Miss: A Cross-System Review
Your patient on metformin, furosemide, omeprazole, escitalopram, and atorvastatin faces simultaneous depletion of B12, magnesium, thiamine, calcium, sodium, and CoQ10. No EHR alert will fire for this pattern. Nobody owns it.
The Gut-Brain Axis: Clinical Evidence for Psychiatric Practice
The microbiome-mood connection is real and biologically plausible. But in 2026, the clinical implications are more modest than the headlines suggest: dietary counseling has good adjunctive evidence, specific probiotic strains show small effects, and GI comorbidity screening should be standard. Here is what the data actually support.
Patient-Specific Evidence: Why Subgroup Data Changes Clinical Decisions
Overall trial results often mask clinically important differences between patient subgroups. Understanding when and how subgroup data changes the decision is essential for truly personalized evidence-based medicine.
SGLT2 Inhibitors in HFpEF with CKD: What the Evidence Shows
A 72-year-old with HFpEF, eGFR 34, type 2 diabetes, and a recent heart failure hospitalization. Should she start an SGLT2 inhibitor? The answer spans three trial programs, and the data are clearer than you might expect.
Showing 1–29 of 29 articles